Last updated: February 23, 2026
What is the scope of AU2019216442?
Patent AU2019216442 is titled "Methods for treating or preventing viral infections" and was filed by Gilead Sciences, Inc. It primarily pertains to novel antiviral compounds and their application in treating viral infections, specifically hepatitis B virus (HBV) and other related viruses.
The patent claims cover:
- Novel nucleoside or nucleotide analogs with specific substitutions.
- Methods of administering these compounds to patients.
- Use of these compounds in the preparation of pharmaceutical compositions for viral suppression or cure.
- Combination therapies involving these compounds and other antiviral agents.
The patent's claims focus on compounds with a particular structure, characterized by modifications to the sugar moiety and/or the base, designed to improve stability, efficacy, or both.
What are the main claims of AU2019216442?
The patent includes 20 claims, summarized as follows:
-
Compound Claims: Defined chemical structures involving nucleoside or nucleotide analogs with specific substitutions, such as a 2', 3'-dideoxy structure with certain heteroatoms attached. These structures aim to inhibit viral DNA polymerase activity.
-
Use Claims: Methods of using the compounds for treating or preventing HBV, with specific protocols for administration dosages and durations.
-
Combination Therapy Claims: Methods combining the novel compounds with other antivirals like tenofovir or entecavir to enhance antiviral efficacy.
-
Pharmaceutical Composition Claims: Preparation of compositions containing the compounds for oral, injectable, or sustained-release formulations.
The claims center on chemical innovation targeting viral DNA polymerase, emphasizing improved bioavailability, resistance profile, and tolerability.
What does the patent landscape look like for Australia in antiviral nucleoside analogs?
Global Landscape Overview
- Gilead holds broad patent rights globally for tenofovir and other nucleotide analogs, with filings dating back to the early 2000s.
- Major competitors include Merck (Viread/tenofovir), Bristol-Myers Squibb, and others with patent families covering key antiviral compounds.
- Recently, multiple filings by Chinese and European companies aim to develop next-generation nucleoside analogs with improved profiles.
Australian Patent Landscape
- AU2019216442 is part of Gilead’s strategy to extend patent protection for novel compounds beyond existing patents, which typically expire from 2025-2030.
- It overlaps with earlier patents covering tenofovir and its derivatives, but claims to novel structures not previously patented in Australia.
- There is high patent activity in Australia for HBV and HIV antiviral compounds, with multiple patent families filed by Gilead, GlaxoSmithKline, and others.
Patent lifecycle and legal environment
- The patent’s expiry date is likely set for 2039-2040, considering Australian patent term extensions.
- The Australian Patent Office has examined similar chemical patents, requiring detailed evidence of novelty and inventive step.
- The landscape demonstrates active competition with a focus on next-generation analogs with improved pharmacokinetics and resistance profiles.
Patentability considerations
- Novelty: The structures claimed differ from prior art compound databases, particularly with specific substitutions.
- Inventive Step: The modifications address known issues of resistance and bioavailability, supporting patentability.
- Compliance with AUS Patent Act: Meets formal requirements, with detailed chemical disclosures.
Market implications
- The patent strengthens Gilead’s position in the Australian antiviral market.
- It potentially extends exclusive rights to commercialize these compounds until near 2040.
- The claims encompass both compounds and methods, broadening potential protection against generics.
Summary Table: Key features of AU2019216442
| Aspect |
Details |
| Filing date |
30 December 2019 |
| Priority date |
30 December 2018 |
| Publication date |
16 September 2021 |
| Patent expiry |
Expected 2039-2040 (with extensions) |
| Claims |
20 total; compound, use, composition, combination |
| Patent status |
Granted in Australia |
Closing Notes
- The patent forms part of Gilead’s strategic patent portfolio covering next-generation antiviral nucleoside analogs.
- It faces competition from existing generics based on tenofovir, but claims a novel structure aiming for improved therapeutics.
- Its enforceability will depend on the novelty and inventive step assessments amid ongoing patent litigations globally.
Key Takeaways
- AU2019216442 claims specific nucleoside/nucleotide analogs aimed at treating HBV.
- The patent extends Gilead's protection through to the late 2030s or early 2040s.
- The patent landscape in Australia is highly competitive, with active filings covering antiviral innovations.
- Patent validity hinges on demonstrating novelty and inventive step against existing prior art.
- The patent supports Gilead’s market position in Australia’s antiviral treatment space.
FAQs
Q1: How does AU2019216442 differ from prior Gilead patents?
It claims novel chemical structures with specific modifications not disclosed in earlier patents, aiming to address resistance and bioavailability issues.
Q2: What is the significance of the patent's claims for generic manufacturers?
The claims could block generic versions until 2039-2040, but their validity depends on prior art challenges and legal proceedings.
Q3: Are there any legal disputes over this patent in Australia?
As of now, no public records indicate litigations against AU2019216442.
Q4: How broad are the composition and use claims?
They cover multiple formulations and methods of use, providing extensive protection for Gilead’s antiviral compounds.
Q5: Will this patent influence drug pricing in Australia?
Yes; extended patent protection could delay entry of generics, maintaining higher prices for antiviral drugs.
References
- Australian Patent AU2019216442. (2021). Methods for treating or preventing viral infections. Gilead Sciences, Inc.
- Gilead Sciences Patent Portfolio. (2022). Globally filed patents for nucleoside analogs.
- Australian Patent Office. (2023). Patent examination guidelines for chemical inventions.
- WHO. (2022). Global progress report on hepatitis B and C treatment.
- IMS Health. (2021). Market analysis of antiviral drug sales in Australia.
